Proposed Ninth Edition TNM Staging System for Lung Cancer: Guide for Radiologists.

Lung cancer continues to be the primary cause of cancer-related deaths globally. Precise staging is imperative for the development of successful treatment approaches and improvement of patient outcomes. Traditionally, lung cancer staging has depended on the TNM staging system, and the International Association for the Study of Lung Cancer (IASLC) has recently recommended modifications.

Update: The Ninth Edition TNM Staging System for Thymic Epithelial Tumors.

- Update articles supplement or update information found in full-length articles previously published in . These updates, written by at least one author of the previous article, provide a brief synopsis that emphasizes important new information such as technological advances, revised imaging protocols, new clinical guidelines involving imaging, or updated classification schemes.

The Ninth Edition TNM Staging Classification for Thymic Epithelial Tumors.

Staging classification is essential in cancer management and is based on three components: tumor extent (T), lymph node involvement (N), and distant metastatic disease (M). For thymic epithelial malignancies, clinical Tumour, Node, Metastasis (cTNM) staging is primarily determined by imaging, making radiologists integral to clinical practice, treatment decisions, and maintaining the quality of staging databases. The ninth edition of the TNM classification for thymic epithelial tumors will be implemented in January 2025.

Imaging of Lung Cancer Staging: TNM 9 Updates.

Imaging plays a key role in clinical staging of lung cancer and guiding therapy. A thorough understanding of the staging system including the nomenclature and updates is necessary to tailor treatment plans and optimize patient care. The 9th edition of the Tumor, Node, Metastasis staging system for lung cancer has no changes for T classification and subdivides N2 and M1c categories.

Thymic Imaging Pitfalls and Strategies for Optimized Diagnosis.

Thymic imaging is challenging because the imaging appearance of a variety of benign and malignant thymic conditions are similar. CT is the most commonly used modality for mediastinal imaging, while MRI and fluorine 18 fluorodeoxyglucose (FDG) PET/CT are helpful when they are tailored to the correct indication. Each of these imaging modalities has limitations and technical pitfalls that may lead to an incorrect diagnosis and mismanagement.